Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple Vasostrict ANDAs Rival Eagle In Competitive Market

‘Market Is Crowded,’ Admits Peptide-Focused ANDA Sponsor Amphastar

Executive Summary

Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.

You may also be interested in...



Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs

With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.

Eagle Vindicated On Vasopressin With US Federal Circuit Decision

Endo’s woes show no sign of abating, with the US Court of Appeals for the Federal Circuit shooting down its appeal against a finding of non-infringement for two key patents shielding its Vasostrict injectable.

Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring

A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel